Another thing I'm curious about is, if PYC can carry in an existing drug - which is approved - and simply does this more effectively, then do they need to go through the full or a lengthy clinical trial process?
It seems to me that on one hand no, because it's approved, but on the other we may not know what impact the different delivery point or efficacy could have.
Any thoughts?
drugs 25 to 50 x more effective, page-12
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 18.8¢ | $963.9K | 4.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2692 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 445208 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |